Cervical cancer
Conditions
Interventions
radical hysterecotmy and perioperative chemotherpy with Docetaxel and Carboplatin
Sponsors
Saitama Medical university International Medical Center
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1.Cervical cancer patients stage IB2, IIA2, IIB, and III 2. Have an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 3. Main medical conditions must be well-controlled 4. Have a life expectancy of at least 3 months, as estimated by the investigator 5. Subject must provide written informed consent and be wiling and able to comply with all aspects of the protocol 6. Laboratory results within the 1 week prior to Registration must be as follows: -Absolute neutrophil count > 1,500 cells/mm3 -Bilirubin < 1.5 mg/dL -Creatinine < 1.5 mg/dL -Asparatate Aminotransferse (AST) and Alanine Aminotransferase (ALT) < 100 U/L -Platelet count > 100,000 cells/mm3 7. Must evaluate MRI and CT scan within 1 month prior to registration
Exclusion criteria
Exclusion criteria: 1. Having fever more than 38.0 degrees 2. Active serious systemic disease, including active bacterial or fungal infection. 3. Clinically siginificant heart disease or other complications. 4. Evidence of other active invasive malignancy. 5. Previous treatment with Taxens and/or Platinums. 6. Any medical or other condition that, in the opinion of the investigator, would preclude the subjects' participation in a clinical study including medical contraindications.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| disease free survival | — |
Countries
Japan
Contacts
Public ContactAkira Kurosaki
Saitama Medical university International Medical Center Gynecogic Oncology
Outcome results
None listed